non-invasive diagnostic technologies

New non-invasive diagnostic technologies in high-risk patients with coronary heart disease, rhythm disturbances and heart failure


  • Gesundheitsforschung
The problem of timely revealing of life-threatening states in patients with coronary heart disease (CHD), the increase of the effectiveness of treatment of severely ill patients with CHD, the decrease of mortality and morbidity of the population working age is gaining a special importance due to the increasing significance of cardiovascular diseases in the mortality structure of the population.

A great deal of attention is attached to the elaboration and development of modern high-technological and cost-effective method of diagnostic of heart failure and rhythm disturbances in patients with CHD having a complex and unfavourable, anatomical, electrophysiological, neurohumoral characteristics of different stages of myocardial remodelling in this category of patients:
  • Biochemical markers (level of natriuretic peptides BNP and proBNP, growth factors etc.), that can severe as an important criterion of diagnostics and prediction of heart failure already at its early stages, as well as the criterion of the ischemia degree in patients with CHD
  • Three-dimensional EchoCG - a modern method of ultrasound heart and coronary arteries visualization, visualization and 3D-reconstruction of cardiac structures, allowing for more accurate evaluation of their state and function
  • Tissue Doppler cardiography - a modern method of evaluation of regional left ventricular contractility, diagnostics of diastolic dysfunction, diagnostics of interventricular and intraventicular desynchronization
  • Multichannel surface ECG-mapping and multichannel magnetic cardiography - modern method of evaluation of electrophysiological state of the heart and localization of pathological processes with the use of the maps of heart electrical and magnetic fields distribution on the body`s surface
The suggested program will permit to form diagnostic algorithms for the assessment of the risk of development of life-threatening states in this category of patients, for the selection of the type of therapy: pharmacological, stimulation of angio/myogenesis using the methods of gene and cell technologies, surgical, interventional, including biventricular stimulation, their combination, as well as for the evaluation of the effectiveness and adequacy of conducted treatment.